我这有很长一段话，请牛人翻译，翻译好的追分！

Question

American Oriental Bioengineering Completes Acquisition of Changchun Xinan Pharmaceutical Group Company Ltd.
NEW YORK, Sept. 6 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ('AOBO'), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, today announced that it has completed the acquisition of Changchun Xinan Pharmaceutical Group Company Limited ('CCXA'). The purchase price for this all cash transaction is approximately USD $28.5 million (RMB 215 million).

CCXA is a privately owned business primarily serving the rural healthcare market with more than 100 plant-based pharmaceutical products in its portfolio. AOBO believes CCXA's leading products will be highly complimentary to its existing product line and will also expand the variety of AOBO's current product offering. CCXA's products cover both the prescription and OTC markets. In 2006, CCXA was profitable and generated approximately USD$9.0 million (68 million RMB) in revenue annually with approximately 40 products contributing to the overall revenue. Some of these products include Nubao, a blood circulation enhancer for treatment of premenstrual syndromes; Kanguzensheng Tablet for the treatment of bone spurs; Yakangling, a plant- based pharmaceutical product that treats gingivitis; and Nanbao, a plant based male sexual drive enhancer.

Tony Liu, Chief Executive Officer of AOBO stated, 'We are pleased to welcome CCXA to our expanding business portfolio. CCXA has promising and profitable products that we intend to leverage across our large distribution network. With over 100 products in its portfolio, CCXA has the opportunity to benefit from the government's efforts to offer affordable pharmaceutical products for its citizens, particularly in rural areas of the country and we are pleased that most of its products are currently covered under the government insurance plan. We intend to identify ways to improve CCXA's operating efficiency, add greater structure to the product line and implement a more beneficial pricing strategy. We look forward to enhancing overall productivity and efficiency in this business.'

Answer 1

美国东方生物工艺学完成长春西南Pharmaceutical Group 有限公司Company 的承购。纽约, American 9月6 日/PRNewswire-FirstCall/ -- Oriental Bioengineering, Inc. (NYSE: AOB) (' AOBO '), 基于植物的配药和nutraceutical 产品的主导的制造商和经销商, 今天宣布, 它完成了长春西南Pharmaceutical Group Company 的承购限制了(' CCXA ') 。购买价为这次所有现金交易是近似地USD $28.5 百万(RMB 215 百万) 。 CCXA 是0N 私有的事务主要为农村医疗保健市场服务与超过100 种基于植物的药品在它的股份单。AOBO 相信CCXA's 主导的产品将是高度赞美对它现有的产品系列, 并且将扩展品种AOBO 的当前产品提供。CCXA's 产品报道处方和OTC 市场。2006 年, CCXA 是有益和近似地引起的USD$9.0 百万(68 百万RMB) 在收支每年与大约40 个产品贡献对整体收支。这些产品包括Nubao, 血液循环改进物为premenstrual 综合症状的治疗; Kanguzensheng 片剂为骨头踢马刺的治疗; Yakangling, 植物根据了对待齿龈炎的药品; 并且Nanbao, 植物根据了男性性驱动改进物。 托尼・刘, AOBO 的首席执行官陈述, ' 我们高兴欢迎CCXA 到我们的扩展企业股份单。CCXA 有我们打算支持横跨我们的大分布式网络的有为和有益的产品。与100 个产品在它的股份单, CCXA 有机会受益于政府的努力提供付得起的药品为它的公民, 特别在国家的乡区并且我们是喜悦的大多它的产品当前被盖根据政府保险计划。我们打算辨认方式改进CCXA's 操作效率, 增加更加巨大的结构来产品系列和实施一个更加有利的定价的战略。我们盼望提高整体生产力和效率在这事务。'

Answer 2

恢复就后果解放后果